Eli Lilly’s Donanemab Receives Tacit Approval for Alzheimer’s Clinical Trial in China
The Center for Drug Evaluation (CDE) website indicates that US major Eli Lilly’s (NYSE: LLY)...
Eli Lilly
Innovent Biologics’ Tyvyt Approved for First-Line Esophageal Squamous Cell Carcinoma
The National Medical Products Administration (NMPA) website indicates that China-based Innovent Biologics, Inc. (HKG: 1801)...
Innovent Biologics and Eli Lilly & Co.’s Tyvyt Achieves Primary Endpoints in Phase II ESCC Clinical Study
Innovent Biologics (HKG: 1801), a prominent biotech firm headquartered in Suzhou, China, and Eli Lilly...